In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioSphere Medical, Inc.

Latest From BioSphere Medical, Inc.

Myovant Spurns Sumitovant Offer, Remains Open To Higher-Value Deal

Sumitovant offered $22.75 per share in cash, valuing Myovant at $2.4bn total, to acquire what it does not hold as a result of its 2019 agreement to buy majority shares of five Roivant companies. 

Deals M & A

Recordati Expands Into Rare Cancer Space With EUSA Pharma Buy

The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.

Companies Deals

Who’s Hired? Another Viatris Executive Joins Neuraxpharm

Neuraxpharm has appoints Viatris’ head of finance in Germany as its new commercial central region officer and country manager to strengthen its position in the German market, while Stada has hired a new head of consumer health in Germany. Meanwhile, the AAM has made multiple key appointments and Hyloris, Siegfried and Mayne Pharma have made top-level additions.

BioPharmaceutical Strategy

FDA Approves Mayne’s Halobetasol Foam For Adolescents

Mayne Pharma has announced receiving US FDA approval for its Lexette (halobetasol propionate) 0.05% foam for the treatment of plaque psoriasis for use in adolescents. With Lexette, Mayne now markets more than twenty dermatology products in the US including four branded products. 

United States BioPharmaceutical
See All

Company Information

UsernamePublicRestriction

Register